Japan Issues New Guidance On Regenerative Medicine
This article was originally published in PharmAsia News
Executive Summary
To encourage development of treatments and medical devices in the Regenerative Medicine area, Japan's Ministry of Health, Labor and Welfare issued new guidance regarding quality and safety in RM development. A follow-up to previous guidance issued in 2000, the new guidance listed points for donor selection, screening of rejections, virus deactivation and removal, and quality management in cellular reproduction. Regarding autologous cells, the guidance calls for individualized measures to prevent confusion and cross contamination. In October 2007, autologous cultured epidermis JACE made by Aichi-based Japan Tissue Engineering Co., received government approval to treat serious burns. (Click for more-Japanese language
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.